Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 2801 - 2808 of 12086 results
Post-Pandemic Access to Telehealth: Highlights of the CMS 2022 Physician Fee Schedule Final Rule
November 11, 2021| Blog| Viewpoint
OIG Revises and Renames the Provider Self-Disclosure Protocol
November 10, 2021| Blog| Viewpoint
Stop the Presses: DOJ Sues to Prevent Monopsony Resulting from Penguin Random House Acquisition of Simon & Schuster
November 9, 2021| Blog| Viewpoint
Ask A Mentor: How Can I Successfully Switch Practices?
November 9, 2021| News
Webinar Recording: Navigating the Rapidly Evolving ESG Landscape: Impacts, Implications, and Strategic Considerations
November 9, 2021| Webinar| Viewpoint
Travel Alert – Update* on U.S. Travel Bans and Travel Requirements
November 9, 2021| Alert| Viewpoint
OSHA Vaccine Rule Temporarily Blocked By Federal Appeals Court
November 7, 2021| Blog| Viewpoint
$1B Power Line Rejection A Reminder Of Grid Project Hurdles
November 5, 2021| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|